Navigation Links
New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development
Date:12/2/2008

SCOTTSDALE, Ariz., Dec. 2 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Parkinson's disease (PD) therapies. This report, entitled Thought Leader Insight & Analysis -- Parkinson's Disease, is based on 9 interviews conducted with PD experts from the US (6) and Europe (3).

"Regardless of whether they're delivered via surgical implants, gene therapies, viral vectors or old-fashioned small molecules, the most dramatic advances in Parkinson's disease therapeutics will be used in early stage disease to prevent loss of functional status and quality of life," says lead author Dr. Jeffrey D. Berk. "Improvements in invasive procedures and new understanding of the pathophysiology of Parkinson's disease are shifting the risk/benefit ratio and opening up new possibilities for patients."

In addition to discussing today's treatment goals, available therapeutic approaches and unmet needs, MedPredict's expert panel explores the current state of the art in new approaches being developed for the symptomatic treatment and disease modification of PD, including:

    -- Unmet needs: dopamine agonists, wearing off vs. dyskinesia, depression,
       pain, dementia, psychosis, neuroprotection, impulse control (punding),
       restless legs syndrome;
    -- Deep brain stimulation (risk/benefit, pharmacoeconomics);
    -- Gene therapies and growth factors (human fetal implants, GDNF,
       neurturin, neublastin, GAD/glutamic acid decarboxylase),
       alpha-synuclein;
    -- Dopamine agonists, monoamine oxidase inhibitors;
    -- Levodopa formulations, COMT inhibitors; and
    -- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA,
       5-HT, anticonvulsants, antihypertensives, farnesyl transferase
       inhibitors.

Companies mentioned in this report include: Acadia, Amersham Pharmacia Biotech/GE Healthcare, Amsterdam Molecular Therapeutics, Bayer-Schering, Bayer-Schering/Titan, Boehringer Ingelheim, Ceregene/Genzyme, Eisai, Elan, Forest, GlaxoSmithKline, GSK/XenoPort/Astellas, Ipsen, Kyowa, Lilly, Link Medicine Corp, Medtronic, Merck-Serono, Merck-Serono/Newron, NeuroDerm, Neurologix, Novartis, NsGene, Ortho-McNeill-Janssen, Pfizer, Qrx Pharma, Schering-Plough, Solvay, Solvay/Wyeth, Teva, UCB, Valeant, and Wyeth.

This report can be purchased by contacting MedPredict (http://www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
2. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
3. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
4. Encorium Reports Third Quarter 2008 Financial Results
5. Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
6. NSD Bio Group, LLC chosen by U.S.-China Economic & Security Review Commission for Report on Chinas High Tech Sectors
7. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
8. SPO Medical Reports Nine Month Period Ending September 2008
9. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
10. Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):